Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...

The news keeps getting better for the new GLP-1 weight-loss drugs fromEli Lilly and Novo Nordisk.

Senast har företaget meddelat att det utvecklar ett viktminskningsläkemedel i ett försök att konkurrera med sådana som Novo Nordisk och Eli Lilly. AbbVie har gjort det bättre än BMW och ...